Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
29
QNTM Quote, Financials, Valuation and Earnings
Last price:
$8.07
Seasonality move
:
18.71%
Day range:
$8.03 - $9.00
52-week range:
$2.89 - $38.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.69x
Volume:
64.4K
Avg. volume:
145.8K
1-year change:
137.82%
Market cap:
$31.9M
Revenue:
--
EPS (TTM):
-$10.26
Analysts' Opinion
-
Consensus RatingQuantum BioPharma Ltd. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $17.23, Quantum BioPharma Ltd. has an estimated upside of 441.45% from its current price of $8.30.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $17.23 representing 100% downside risk from its current price of $8.30.
Fair Value
-
According to the consensus of 1 analyst, Quantum BioPharma Ltd. has 441.45% upside to fair value with a price target of $17.23 per share.
QNTM vs. S&P 500
-
Over the past 5 trading days, Quantum BioPharma Ltd. has underperformed the S&P 500 by -7.19% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Quantum BioPharma Ltd. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Quantum BioPharma Ltd. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Quantum BioPharma Ltd. reported revenues of --.
Earnings Growth
-
Quantum BioPharma Ltd. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Quantum BioPharma Ltd. reported earnings per share of -$1.40.
Enterprise value:
27M
EV / Invested capital:
2.68x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.16x
EV / Free cash flow:
-3.08x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$529.2K
Return On Assets:
-178.39%
Net Income Margin (TTM):
--
Return On Equity:
-360.06%
Return On Invested Capital:
-304.33%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$3.5M | -$500K | -$529.2K | -$120.8K | -$145.3K | |
| Operating Income | -$24M | -$11.8M | -$18.9M | -$4.1M | -$4.7M | |
| EBITDA | -$20.4M | -$11.3M | -$18.4M | -$4M | -$4.5M | |
| Diluted EPS | -$12.67 | -$14.87 | -$10.26 | -$4.17 | -$1.40 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $49.9M | $25.2M | $9.2M | $13.8M | $9.3M | |
| Total Assets | $68.7M | $43.6M | $18.9M | $19M | $14.2M | |
| Current Liabilities | $8.5M | $7.4M | $4.2M | $3.7M | $6.6M | |
| Total Liabilities | $8.5M | $7.4M | $4.2M | $3.7M | $6.6M | |
| Total Equity | $60.2M | $36.1M | $14.7M | $15.3M | $7.5M | |
| Total Debt | $97.2K | $256.4K | $62.3K | $72.5K | $151.8K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$16.3M | -$6.9M | -$8.8M | -$3.4M | -$1.7M | |
| Cash From Investing | -$473.4K | -$2.7M | -$1.1M | -$3.5M | $422.9K | |
| Cash From Financing | -$3.2M | $9.1M | $7M | $6.7M | $252K | |
| Free Cash Flow | -$16.3M | -$6.9M | -$8.8M | -$3.4M | -$1.7M | |
QNTM
Sector
Market Cap
$31.9M
$28.2M
Price % of 52-Week High
21.7%
50.25%
Dividend Yield
0%
0%
Shareholder Yield
-3.01%
-1.54%
1-Year Price Total Return
137.82%
-18.1%
Beta (5-Year)
0.153
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$8.97
200-day SMA
Sell
Level
$13.94
Bollinger Bands (100)
Sell
Level
8.92 - 19.06
Chaikin Money Flow
Buy
Level
16.5M
20-day SMA
Sell
Level
$9.41
Relative Strength Index (RSI14)
Sell
Level
44.43
ADX Line
Sell
Level
17.36
Williams %R
Buy
Level
-80.3547
50-day SMA
Sell
Level
$9.91
MACD (12, 26)
Sell
Level
-0.24
25-day Aroon Oscillator
Buy
Level
16
On Balance Volume
Neutral
Level
166.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-16.0002)
Sell
CA Score
(Annual)
Level (-3.6209)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (7.3606)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Quantum BioPharma Ltd. is a biopharmaceutical company, which engages in building a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. It operates through the Biopharmaceutical and Strategic Investments segments. The Biopharmaceutical segment focuses on furthering the research and development of the drug candidates and the development of a treatment for alcohol misuse for application in hospitals and other medical practices. The Strategic Investments segment is involved in the generation of returns and cash flow through the issuance of loans secured by residential property, with FSD Strategic Investments having a first or second collateral mortgage on the secured property. The company was founded by Thomas Fairfull, Zeeshan Saeed, and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.
Stock Forecast FAQ
In the current month, QNTM has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The QNTM average analyst price target in the past 3 months is $17.23.
-
Where Will Quantum BioPharma Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Quantum BioPharma Ltd. share price will rise to $17.23 per share over the next 12 months.
-
What Do Analysts Say About Quantum BioPharma Ltd.?
Analysts are divided on their view about Quantum BioPharma Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Quantum BioPharma Ltd. is a Sell and believe this share price will drop from its current level to $17.23.
-
What Is Quantum BioPharma Ltd.'s Price Target?
The price target for Quantum BioPharma Ltd. over the next 1-year time period is forecast to be $17.23 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is QNTM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Quantum BioPharma Ltd. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of QNTM?
You can purchase shares of Quantum BioPharma Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Quantum BioPharma Ltd. shares.
-
What Is The Quantum BioPharma Ltd. Share Price Today?
Quantum BioPharma Ltd. was last trading at $8.07 per share. This represents the most recent stock quote for Quantum BioPharma Ltd.. Yesterday, Quantum BioPharma Ltd. closed at $8.30 per share.
-
How To Buy Quantum BioPharma Ltd. Stock Online?
In order to purchase Quantum BioPharma Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get QNTM Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
QNTM
Sector
P/E ratio
--
23.92x
PEG ratio
-0.16x
-0.01x
P/B ratio
3.69x
1.83x
Price / LTM sales
--
1.61x
Growth Metrics
QNTM
Sector
Revenue growth
--
4.6%
Earnings growth
66.44%
10.88%
Revenue (5-year growth)
--
6.46%
Earnings forecast
-$2.69
-$0.21
Profitability
QNTM
Sector
Profitability FY 2024
-$490.6K
$3.5M
Return on invested capital
-304.33%
-31.84%
Return on assets
-178.39%
-27.96%
Return on equity
-360.06%
-37.63%
Earnings Date
Last Earnings Date
Dec
29
Next Earnings Date
Dec
29
Estimated Next Earnings Date
Mar
30
Balance Sheet
QNTM
Sector
Total cash
$6.3M
$26.3M
Short term investments
$1.2M
$25.7M
Total assets
$17.1M
$76.9M
Long term debt
$151.8K
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 29
Galecto, Inc. [GLTO] is down 12.13% over the past day.
Sell
20
SMX alert for Dec 29
SMX (Security Matters) Plc [SMX] is down 27.67% over the past day.
Sell
11
CDNAF alert for Dec 29
Canadian Tire Corp. Ltd. [CDNAF] is up 11.94% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
